The Flow Cytometry Core Facility (FCCP) provides state-of-the-art flow cytometry services to researchers at the Cancer Center. Extensive user support is provided, consisting of daily instrument startup, maintenance and quality control;easy and reliable online scheduling systems;extensive training options;a site license for FlowJo analysis software;one-on-one consultations between individual researchers and Core Facility staff. These services include Operator-Assisted analysis on FACSCalibur and CyAn, Operator-Assisted cell sorting on two Aria and two MoFlo cell sorters, as well as User-Operated analysis on FACSCalibur, LSR II and Fortessa and User-Operated cell sorting on two Aria cell sorters. The combination of equipment and user support offers researchers opportunity to integrate flow cytometric analysis and cell sorting into their research projects. FCCP provides easy access to purified cell populations and to analysis of cellular subsets and processes, essential elements of many modern cell biology research projects. The presence of FCCP therefore plays an important role in the Center's capability to increase our knowledge of the processes that give rise to cancer, and to improve cancer diagnosis and therapy. The services and collaborative work provided by the FCCF has supported the research of 111 investigators in the past year. During the past grant period the work of the Core has contributed to 450 publications of researchers from 8 research programs. For example, the Flow Core was essential in helping the Rudensky lab demonstrate that regulatory T(Treg) cells integrate environmental cues that suppress particular types of Inflammation. These studies showed that Treg cell-mediated suppression of Th17-driven pathology is facilitated by activation of STAT3 downstream of interleukin 10-R (IL-1 OR) engagement of interleukin 10 (IL-10). This study demonstrated that IL-10 endows Treg cells with the ability to suppress pathogenic Thi7 cell responses. For these studies the Core provided expert flow analysis of STAT3 staining and cell sorting of Fox3-YFPT+ and Fox3-TFP- cells.

Public Health Relevance

The FCCF provides essential services and instrumentation that enable Center investigators to simultaneously analyze multiple characteristics on large numbers of cells and to Isolate highly purified populations of cells that have specific features.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA008748-48
Application #
8933486
Study Section
Subcommittee G - Education (NCI)
Program Officer
Shafik, Hasnaa
Project Start
2014-01-01
Project End
2018-12-31
Budget Start
2014-01-01
Budget End
2014-12-31
Support Year
48
Fiscal Year
2014
Total Cost
$362,498
Indirect Cost
$158,504
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Hsin, Jing-Ping; Lu, Yuheng; Loeb, Gabriel B et al. (2018) The effect of cellular context on miR-155-mediated gene regulation in four major immune cell types. Nat Immunol 19:1137-1145
Senders, Max L; Hernot, Sophie; Carlucci, Giuseppe et al. (2018) Nanobody-Facilitated Multiparametric PET/MRI Phenotyping of Atherosclerosis. JACC Cardiovasc Imaging :
Rogers, Emma M; Connolly, Karen L; Nehal, Kishwer S et al. (2018) Comorbidity scores associated with limited life expectancy in the very elderly with nonmelanoma skin cancer. J Am Acad Dermatol 78:1119-1124
Flinn, Ian W; O'Brien, Susan; Kahl, Brad et al. (2018) Duvelisib, a novel oral dual inhibitor of PI3K-?,?, is clinically active in advanced hematologic malignancies. Blood 131:877-887
Gay, Hiram A; Oh, Jung Hun; Apte, Aditya P et al. (2018) Predictors of acute throat or esophageal patient reported pain during radiation therapy for head and neck cancer. Clin Transl Radiat Oncol 13:1-6
Touijer, Karim A; Karnes, Robert Jeffery; Passoni, Niccolo et al. (2018) Survival Outcomes of Men with Lymph Node-positive Prostate Cancer After Radical Prostatectomy: A Comparative Analysis of Different Postoperative Management Strategies. Eur Urol 73:890-896
Pianko, Matthew J; Moskowitz, Alison J; Lesokhin, Alexander M (2018) Immunotherapy of Lymphoma and Myeloma: Facts and Hopes. Clin Cancer Res 24:1002-1010
Bucciarelli, Peter R; Tan, Kay See; Chudgar, Neel P et al. (2018) BRMS1 Expression in Surgically Resected Lung Adenocarcinoma Predicts Future Metastases and Is Associated with a Poor Prognosis. J Thorac Oncol 13:73-84
Yang, Annie; Baxi, Shrujal; Korenstein, Deborah (2018) ClinicalTrials.gov for Facilitating Rapid Understanding of Potential Harms of New Drugs: The Case of Checkpoint Inhibitors. J Oncol Pract 14:72-76
Mikropoulos, Christos; Selkirk, Christina G Hutten; Saya, Sibel et al. (2018) Prostate-specific antigen velocity in a prospective prostate cancer screening study of men with genetic predisposition. Br J Cancer 118:266-276

Showing the most recent 10 out of 8799 publications